01 / DESIGN
What was studied?
STEP 5 randomized 304 adults with obesity or overweight and a related condition, without diabetes. Both groups received behavioral intervention for 104 weeks.
02 / FINDINGS
What did the researchers report?
Average weight reduction remained greater with semaglutide than placebo at two years. Gastrointestinal adverse events were more frequent in the semaglutide group.
03 / LIMITS
How should it be interpreted?
This is evidence during continued treatment and follow-up, not evidence that the change remains after withdrawal. Most participants were White and female, which is relevant when considering how broadly results apply.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.